[go: up one dir, main page]

WO2000055321B1 - Vertebrate protein slit, dna sequence encoding it and uses thereof - Google Patents

Vertebrate protein slit, dna sequence encoding it and uses thereof

Info

Publication number
WO2000055321B1
WO2000055321B1 PCT/US2000/007040 US0007040W WO0055321B1 WO 2000055321 B1 WO2000055321 B1 WO 2000055321B1 US 0007040 W US0007040 W US 0007040W WO 0055321 B1 WO0055321 B1 WO 0055321B1
Authority
WO
WIPO (PCT)
Prior art keywords
protein
cells
slit
polynucleotide
host cell
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2000/007040
Other languages
French (fr)
Other versions
WO2000055321A3 (en
WO2000055321A2 (en
Inventor
Yi Rao
Jane Y Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
University of Washington
Washington University in St Louis WUSTL
Original Assignee
University of Washington
Washington University in St Louis WUSTL
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by University of Washington, Washington University in St Louis WUSTL filed Critical University of Washington
Priority to EP00916449A priority Critical patent/EP1163336A2/en
Priority to AU37551/00A priority patent/AU3755100A/en
Priority to CA002365214A priority patent/CA2365214A1/en
Priority to JP2000605739A priority patent/JP2002538823A/en
Publication of WO2000055321A2 publication Critical patent/WO2000055321A2/en
Publication of WO2000055321A3 publication Critical patent/WO2000055321A3/en
Publication of WO2000055321B1 publication Critical patent/WO2000055321B1/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07KPEPTIDES
    • C07K14/00Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/475Growth factors; Growth regulators
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00Drugs for disorders of the urinary system
    • A61P13/12Drugs for disorders of the urinary system of the kidneys
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • A61P17/02Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/28Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12Antivirals
    • A61P31/14Antivirals for RNA viruses
    • A61P31/18Antivirals for RNA viruses for HIV
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00Drugs for immunological or allergic disorders
    • A61P37/02Immunomodulators
    • A61P37/06Immunosuppressants, e.g. drugs for graft rejection
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00Drugs for disorders of the cardiovascular system
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Biomedical Technology (AREA)
  • Virology (AREA)
  • Molecular Biology (AREA)
  • Pulmonology (AREA)
  • Oncology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Communicable Diseases (AREA)
  • Transplantation (AREA)
  • Hospice & Palliative Care (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Psychiatry (AREA)
  • Toxicology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Urology & Nephrology (AREA)
  • AIDS & HIV (AREA)

Abstract

Polynucleotides that encode the Xenopus slit protein along with the deduced amino acid sequence of the Xenopus slit protein are given. Recombinant polynucleotides, vectors and transformed cells containing the slit polynucleotide are disclosed. Methods for production of slit proteins, pharmaceutical compounds containing slit protein and therapeutic uses for slit protein are also given. Methods for the repulsive guidance of nerve axon growth and inhibition of cell migration using slit are provided. Methods of stimulating cell proliferation using slit are given, along with methods and compositions for reducing the use of serum in cell culture by the use of slit.

Claims

56
AMENDED CLAIMS
[received by the International Bureau on 20 February 2001 (20.02.01); original claims 10, 11 and 15 amended; remaining claims unchanged (2 pages)]
6. Λ host cell comprising the recombinant vector of claim 3.
7 The host cell of claim 6, wherein said host cell is selected from the group consisting of mammalian cells, plant cells, insect cells, ycasl, bacteria, bacteriophage.
8. The host cell of claim 6, wherein said host cell expresses a protein encoded by said vector,
9. The host cell of claim 8, wherein said expressed protein is secreted by said host cell.
10 A protein or polypcptide fragment encoded by the polynucleotide selected from the group consisting of:
(a) a polynucleotide of SEQ ID NO; 1;
(b) a polynucleotide that has at least 90% sequence identity with the polynucleotide of (a);
(c) a polynucleoluic that hybridizes to the polynucleotide of (a) under conditions of 5X SSC, 50% formamide and 42 °C, and which encodes a protein havmg the same biological function;
(d) a polynucleotide encoding the same amino acid sequence as (a), but which exhibits regular degeneracy in accordance with the degeneracy ofthe genetic code;
(e) a polynucleotide encoding the same amino acid sequence as (b), but which exhibits regular degeneracy in accordance with the degeneracy ofthe genetic code; and (f) a polynucleotide encoding the same amino acid sequence as (c), but which exhibits regular degeneracy in accordance with the degeneracy ofthe genetic code.
11. A protein comprising the amino acid sequence of SEQ ID NO: 2 or a fragment of
SEQ ID NO; 2 and having the same biological function as the protein of SEQ ID NO: 2.
MENDED SHEET (ARTICLE 19T 57
12 '[ he protein of claim 10, wherein one or more of the amino acids have been substituted with a conserved amino acid and the biological function ofthe protein has been maintained.
1 . The protein of claim 10, wherein one of more ofthe amino acid resides includes a substilucnt group.
14. A method fur the production of a puri ficd slit protein comprising growing host cells of claim 8 under conditions where said host cells express a protein encoded by said rccombmant vector and isolating said expressed protein.
15. A pharmaceutical composition comprising the protein of claim 10, a protein fragment thereof having the same biological function, or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable carrier, diluent, or excipient.
16. A method for altering cell migration comprising administering a migration altering amount of a slit protein or a pharmaceutically acceptable salt thereof.
17. The method of claim 16 wherein said sht protein is the protein of claim 10.
18. The method of claim 16, wherein said alteration is by repulsion,
19. The method of claim 16, wherein said alteration is by inhibition,
20. The method of claim 16, wherein said cells express the roundabout (robo) protein
21. The method of claim 16, wherein said cells are neural cells.
22. The method of claim 16, wherein said cells are malignant cells.
23. The method of claim 16, wherein said cells are leukocytes.
PCT/US2000/007040 1999-03-17 2000-03-16 Vertebrate protein slit, dna sequence encoding it and uses thereof Ceased WO2000055321A2 (en)

Priority Applications (4)

Application Number Priority Date Filing Date Title
EP00916449A EP1163336A2 (en) 1999-03-17 2000-03-16 Vertebrate protein slit, dna sequence encoding it and uses thereof
AU37551/00A AU3755100A (en) 1999-03-17 2000-03-16 Vertebrate slit dna sequence, protein and uses thereof
CA002365214A CA2365214A1 (en) 1999-03-17 2000-03-16 Vertebrate protein slit, dna sequence encoding it and uses thereof
JP2000605739A JP2002538823A (en) 1999-03-17 2000-03-16 Vertebrate slit DNA sequences, proteins and uses thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US12476799P 1999-03-17 1999-03-17
US60/124,767 1999-03-17

Publications (3)

Publication Number Publication Date
WO2000055321A2 WO2000055321A2 (en) 2000-09-21
WO2000055321A3 WO2000055321A3 (en) 2001-06-28
WO2000055321B1 true WO2000055321B1 (en) 2001-07-19

Family

ID=22416700

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2000/007040 Ceased WO2000055321A2 (en) 1999-03-17 2000-03-16 Vertebrate protein slit, dna sequence encoding it and uses thereof

Country Status (5)

Country Link
EP (1) EP1163336A2 (en)
JP (1) JP2002538823A (en)
AU (1) AU3755100A (en)
CA (1) CA2365214A1 (en)
WO (1) WO2000055321A2 (en)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU754982B2 (en) * 1999-03-18 2002-11-28 Regents Of The University Of California, The Compositions for promoting nerve regeneration
EP2036921A1 (en) * 2007-09-14 2009-03-18 Scil Technology GmbH Use of Slit, nephrin, ephrin or semaphorin for treatment of cartilage diseases
CA2699411A1 (en) * 2007-09-14 2009-03-19 Scil Technology Gmbh Neuroendocrine factors for treatment of degenerative diseases
WO2014194402A1 (en) 2013-06-04 2014-12-11 The Hospital For Sick Children Methods and uses of slit for treating fibrosis

Family Cites Families (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1992010518A1 (en) * 1990-12-07 1992-06-25 Yale University Purified slit protein and sequence elements thereof

Also Published As

Publication number Publication date
CA2365214A1 (en) 2000-09-21
WO2000055321A3 (en) 2001-06-28
JP2002538823A (en) 2002-11-19
AU3755100A (en) 2000-10-04
EP1163336A2 (en) 2001-12-19
WO2000055321A2 (en) 2000-09-21

Similar Documents

Publication Publication Date Title
KR100205078B1 (en) Basic fibroblast growth factor and the method of preparing the same
CA2195799C (en) Bacterial production of hydrophobic polypeptides
US8557768B1 (en) Human nerve growth factor by recombinant technology
JP2882775B2 (en) Human-glia-derived neurite factor
KR100191697B1 (en) Enzymatic Preparation of Basic Fibroblast Growth Factor
NZ207337A (en) Human nerve growth factor (hngf), prepared by recombinant technology
CZ287810B6 (en) DNA sequence, DNA recombinant molecule containing thereof, process for preparing a protein from the TGF-beta substance group, pharmaceutical preparation in which the protein is comprised, antibody or a fragment thereof and use of the antibody
BR9712348A (en) isolated polynucleotide molecule, expression vector, cultured cell into which an expression vector was introduced, process to produce an isolated fgf homologous polypeptide, isolated fgf homologous polypeptide, pharmaceutical composition, antibody, processes to stimulate ex vivo myocyte progenitor cells, and, paralyzing an agent or drug selectively for heart tissue.
CA2257839A1 (en) Gamma-heregulin
AU704515C (en) Novel protein and process for producing the same
KR927002375A (en) Megakaryocyte forming factor
EP0769020A1 (en) NEW hIL-4 MUTANT PROTEINS USED AS ANTAGONISTS OR PARTIAL AGONISTS OF HUMAN INTERLEUKIN 4
WO1989004832A1 (en) Analogs of fibroblast growth factor
KR950704356A (en) Progenitor B CELL STIMULATING FACTOR
CA2461443A1 (en) Nucleic acid and amino acid sequences encoding high-level expressor factor viii polypeptides and methods of use
EP0476233B1 (en) Human MK gene and protein sequence
US6511823B1 (en) Heparin binding neurotrophic factor gene sequence
KR910002520B1 (en) Cell growth inhibitory factor
Kono et al. Eclosion hormone of the silkworm Bombyx mori Expression in Escherichia coli and location of disulfide bonds
DE69837507T2 (en) Human hedgehog protein
WO2000055321B1 (en) Vertebrate protein slit, dna sequence encoding it and uses thereof
CN1504573A (en) Confluent protein capable of self-cracking into polypeptide with antibiosis and reparation function
Jung et al. Biochemical and molecular characterization of an antifungal protein from Tenebrio molitor larvae
CA2223503A1 (en) Transferrin receptor genes
Chakraborty et al. Overexpression, purification and characterization of recombinant salmon calcitonin, a therapeutic protein, in streptomyces avermitilis

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
AK Designated states

Kind code of ref document: A3

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: A3

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

AK Designated states

Kind code of ref document: B1

Designated state(s): AE AL AM AT AU AZ BA BB BG BR BY CA CH CN CR CU CZ DE DK DM EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG UZ VN YU ZA ZW

AL Designated countries for regional patents

Kind code of ref document: B1

Designated state(s): GH GM KE LS MW SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG

B Later publication of amended claims
WWE Wipo information: entry into national phase

Ref document number: 37551/00

Country of ref document: AU

ENP Entry into the national phase in:

Ref document number: 2365214

Country of ref document: CA

Ref country code: CA

Ref document number: 2365214

Kind code of ref document: A

Format of ref document f/p: F

ENP Entry into the national phase in:

Ref country code: JP

Ref document number: 2000 605739

Kind code of ref document: A

Format of ref document f/p: F

WWE Wipo information: entry into national phase

Ref document number: 2000916449

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2000916449

Country of ref document: EP

REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWW Wipo information: withdrawn in national office

Ref document number: 2000916449

Country of ref document: EP